5-APDB
| Clinical data | |
|---|---|
| Routes of administration | Oral | 
| ATC code | 
 | 
| Legal status | |
| Legal status | 
 | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C11H15NO | 
| Molar mass | 177.247 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
| (what is this?) (verify) | |
5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB, 3-Desoxy-MDA, EMA-4) is a putative entactogen drug of the phenethylamine and amphetamine classes. It is an analogue of MDA where the heterocyclic 3-position oxygen from the 3,4-methylenedioxy ring has been replaced by a methylene bridge. 6-APDB is an analogue of 5-APDB where the 4-position oxygen has been replaced by a methylene bridge instead. 5-APDB was developed by a team led by David E. Nichols at Purdue University as part of their research into non-neurotoxic analogues of MDMA.